Allied Corp. (ALID)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Allied Corp. (ALID) with AI Score 39/100 (Weak). Allied Corp. is a cannabis company focused on developing, manufacturing, and marketing hemp-derived cannabis products in the United States. The company operates through Allied Colombia and Allied Corp. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Allied Corp. (ALID) Healthcare & Pipeline Overview
Allied Corp. operates within the cannabis industry, focusing on hemp-derived CBD products and the development of treatments for mental health conditions like PTSD. The company's dual-segment structure allows for targeted operations in both Colombia and the United States, addressing the growing market for cannabis-related health and wellness solutions.
Investment Thesis
Allied Corp. presents a speculative investment thesis centered on its development of novel treatments for PTSD and its existing line of hemp-derived CBD products. The company's focus on ALID 10 and ALID 11 offers potential upside if clinical trials demonstrate efficacy and regulatory approvals are secured. However, the company's current market capitalization of $0.00B and negative free cash flow of $-0.00B indicate significant financial challenges. The company's success hinges on navigating the complex regulatory landscape of the cannabis industry and successfully commercializing its products. Investors should carefully consider the risks associated with investing in a small-cap company in a rapidly evolving industry.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap: $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Free Cash Flow: $-0.00B reflects the company's current need for external funding to sustain operations and growth initiatives.
- Beta: -0.82 suggests the stock is less volatile than the market, but this may also reflect limited trading activity.
- Operates in two segments: Allied Colombia and Allied Corp., allowing for focused operations in cultivation/production and product development/distribution, respectively.
- Developing ALID 10 and ALID 11 for PTSD treatment, representing a high-potential, high-risk venture into pharmaceutical applications of cannabis.
Competitors & Peers
Strengths
- Focus on developing treatments for PTSD.
- Operates in two distinct segments.
- Offers a range of hemp-based CBD products.
- Established presence in the US market.
Weaknesses
- Limited financial resources.
- Negative free cash flow.
- Small market capitalization.
- Reliance on OTC market for trading.
Catalysts
- Upcoming: Clinical trial results for ALID 10 and ALID 11 for PTSD treatment.
- Ongoing: Expansion of distribution network for CBD products.
- Ongoing: Regulatory developments in the cannabis industry.
- Upcoming: Potential partnerships with other companies in the cannabis space.
- Ongoing: Development of new CBD-based products.
Risks
- Potential: Regulatory changes in the cannabis industry could negatively impact the company's operations.
- Ongoing: Competition from larger cannabis companies with greater resources.
- Potential: Failure to obtain regulatory approval for ALID 10 and ALID 11.
- Ongoing: Limited financial resources and negative free cash flow.
- Potential: Fluctuations in the price of hemp and CBD.
Growth Opportunities
- Expansion of CBD Product Line: Allied Corp. has the opportunity to expand its line of hemp-based CBD natural health products, including beauty and skincare products, and foods and beverages. The global CBD market is projected to reach billions of dollars in the coming years, driven by increasing consumer demand for natural health and wellness products. By introducing new and innovative CBD products, Allied Corp. can capture a larger share of this growing market. Timeline: Ongoing.
- Development and Commercialization of ALID 10 and ALID 11: Allied Corp.'s development of ALID 10 and ALID 11 for the treatment of PTSD represents a significant growth opportunity. PTSD affects millions of people worldwide, and there is a significant unmet need for effective treatments. If Allied Corp. can successfully develop and commercialize these treatments, it could generate substantial revenue and establish itself as a leader in the field of cannabis-based pharmaceuticals. Timeline: 3-5 years.
- Strategic Partnerships: Allied Corp. can pursue strategic partnerships with other companies in the cannabis industry, such as cultivators, manufacturers, and distributors. These partnerships can help Allied Corp. to expand its reach, access new markets, and improve its operational efficiency. For example, a partnership with a large distributor could help Allied Corp. to get its products into more retail stores. Timeline: Ongoing.
- International Expansion: Allied Corp. can expand its operations into new international markets. The cannabis industry is growing rapidly in many countries around the world, and Allied Corp. can capitalize on this growth by establishing a presence in these markets. However, it is important to carefully consider the regulatory environment in each country before entering a new market. Timeline: 2-3 years.
- Research and Development: Allied Corp. can continue to invest in research and development to develop new and innovative cannabis-based products and treatments. This will help Allied Corp. to stay ahead of the competition and maintain its position as a leader in the cannabis industry. For example, Allied Corp. could invest in research to develop new strains of cannabis with specific therapeutic properties. Timeline: Ongoing.
Opportunities
- Expansion of CBD product line.
- Commercialization of ALID 10 and ALID 11.
- Strategic partnerships.
- International expansion.
Threats
- Regulatory changes in the cannabis industry.
- Competition from larger cannabis companies.
- Challenges in obtaining regulatory approval for ALID 10 and ALID 11.
- Fluctuations in the price of hemp and CBD.
Competitive Advantages
- Proprietary formulations for CBD products.
- Intellectual property related to ALID 10 and ALID 11.
- Established presence in the US market for hemp-derived products.
About ALID
Allied Corp., headquartered in Kelowna, Canada, is a cannabis company engaged in the development, manufacture, and marketing of hemp-derived cannabis products primarily in the United States. The company operates through two distinct segments: Allied Colombia and Allied Corp. These segments allow the company to focus on different aspects of the cannabis market, from cultivation and production to product development and distribution. Allied Corp. offers a range of hemp-based CBD natural health products, including beauty and skincare products, as well as foods and beverages. A key aspect of Allied Corp.'s business is its research and development efforts, particularly in the area of mental health. The company is developing ALID 10 and ALID 11, novel treatments for post-traumatic stress disorder (PTSD) and related mental health conditions. These treatments target the 5-HT2 receptor and related physiological pathways, representing a potentially innovative approach to addressing these conditions. Allied Corp. aims to establish itself as a leader in the cannabis industry by providing high-quality products and developing innovative treatments for unmet medical needs.
What They Do
- Develops hemp-derived cannabis products.
- Manufactures hemp-derived cannabis products.
- Markets hemp-derived cannabis products in the United States.
- Operates in two segments: Allied Colombia and Allied Corp.
- Offers hemp-based CBD natural health products.
- Develops beauty and skincare products.
- Develops foods and beverages.
- Develops ALID 10 and ALID 11 for PTSD treatment.
Business Model
- Develops and manufactures hemp-derived cannabis products.
- Markets and sells these products directly to consumers and through retail channels.
- Generates revenue through the sale of CBD products, beauty and skincare items, and potentially pharmaceuticals.
Industry Context
Allied Corp. operates in the rapidly evolving cannabis industry, which is experiencing significant growth and regulatory changes. The market for CBD products is expanding, driven by increasing consumer awareness of the potential health benefits of cannabis. However, the industry is also highly competitive, with numerous companies vying for market share. Allied Corp.'s focus on developing treatments for PTSD differentiates it from many of its competitors, but also exposes it to the risks associated with pharmaceutical development and regulatory approval. The company's success will depend on its ability to navigate the complex regulatory landscape and effectively market its products.
Key Customers
- Consumers seeking natural health and wellness products.
- Individuals looking for alternative treatments for mental health conditions.
- Retailers who sell CBD products and related items.
Financials
Chart & Info
Allied Corp. (ALID) stock price: Price data unavailable
Latest News
No recent news available for ALID.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALID.
Price Targets
Wall Street price target analysis for ALID.
MoonshotScore
What does this score mean?
The MoonshotScore rates ALID's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
ALID OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Allied Corp. may not meet the minimum financial standards or reporting requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and prospects. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low liquidity and high price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Going concern risk.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Confirm share structure and outstanding shares.
- Company has a functional website.
- Company has a physical address and contact information.
- Company has a detailed business plan.
- Company is actively developing and marketing products.
- Company has a management team with relevant experience.
ALID Healthcare Stock FAQ
What does Allied Corp. do?
Allied Corp. is a cannabis company that focuses on developing, manufacturing, and marketing hemp-derived cannabis products in the United States. The company operates through two segments, Allied Colombia and Allied Corp., offering a range of hemp-based CBD natural health products, including beauty and skincare items, as well as foods and beverages. Additionally, Allied Corp. is involved in the research and development of novel treatments for mental health conditions, such as PTSD, with its ALID 10 and ALID 11 programs.
What do analysts say about ALID stock?
Currently, there is no available analyst coverage for Allied Corp. (ALID) due to its small market capitalization and OTC listing. Investors should conduct their own thorough research and due diligence before investing in ALID stock. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, are not readily available due to the company's financial situation. Growth considerations include the potential success of ALID 10 and ALID 11 and expansion of its CBD product line.
What are the main risks for ALID?
Investing in Allied Corp. carries several risks, including regulatory uncertainty in the cannabis industry, competition from larger companies, and the potential failure to obtain regulatory approval for its pharmaceutical products. The company's limited financial resources and negative free cash flow also pose significant risks. Furthermore, as an OTC-listed stock, ALID is subject to lower liquidity and higher price volatility compared to stocks listed on major exchanges. Investors should carefully consider these risks before investing.
What revenue streams does Allied Corp. have in healthcare?
Allied Corp.'s current revenue streams in the healthcare sector are primarily derived from the sale of hemp-based CBD natural health products. These products include beauty and skincare items, as well as foods and beverages containing CBD. The company anticipates future revenue streams from its pharmaceutical development programs, specifically ALID 10 and ALID 11, if these treatments receive regulatory approval and are successfully commercialized for the treatment of PTSD and related mental health conditions. The timeline for these future revenue streams is uncertain.
How does Allied Corp. navigate regulatory approval processes?
As a company developing potential pharmaceutical treatments, Allied Corp. will need to navigate rigorous regulatory approval processes in both the United States and other relevant jurisdictions. This includes conducting preclinical and clinical trials to demonstrate the safety and efficacy of ALID 10 and ALID 11. The company will need to comply with regulations set forth by agencies such as the FDA in the United States. Allied Corp.'s success depends on its ability to meet these regulatory requirements and obtain the necessary approvals to commercialize its pharmaceutical products. The company's regulatory track record is currently limited, as it has not yet brought any pharmaceutical products to market.
What are the key factors to evaluate for ALID?
Allied Corp. (ALID) currently holds an AI score of 39/100, indicating low score. Key strength: Focus on developing treatments for PTSD.. Primary risk to monitor: Potential: Regulatory changes in the cannabis industry could negatively impact the company's operations.. This is not financial advice.
How frequently does ALID data refresh on this page?
ALID prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ALID's recent stock price performance?
Recent price movement in Allied Corp. (ALID) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on developing treatments for PTSD.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on limited information available for OTC-listed companies.
- Analyst consensus is not available due to lack of coverage.
- OTC analysis is based on general characteristics of the OTC Other tier.